Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3086646 | 0.88 | MAPT (0.31) | — | |
| SCHEMBL3090836 | 0.85 | LTA4H (0.41) | POLBNPC1GAARAB9A | |
| SCHEMBL3084778 | 0.85 | SLC6A4 (0.35) | NPC1RAB9A | |
| SCHEMBL3082717 | 0.71 | LMNA (0.34) | NPC1RAB9A | |
| SCHEMBL3084411 | 0.71 | LMNA (0.31) | NPC1RAB9A | |
| SCHEMBL3087658 | 0.66 | CYP1A2 (0.35) | — | |
| SCHEMBL407272 | 0.65 | KDM4E (0.31) | — | |
| SCHEMBL3084755 | 0.64 | TYMP (0.34) | — | |
| SCHEMBL3088499 | 0.63 | THRA (0.31) | — | |
| SCHEMBL3092196 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207134-B2 | Fused ring spiroketal derivative and use thereof as anti-diabetic drug | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20100234609-A1 | FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2048152-A1 | FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS DRUG FOR TREATING DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234609-A1 | FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG | REN, WNK1, GCKR | POLB 4613/4885NPC1 2342/4885GAA 2262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.